Stem cell mobilization by G-CSF and stabilization of cardiac SDF-1 by genetic or pharmacological DPP4 inhibition (i.e., the therapeutic concept of dual strengthening strategies on stem cell therapy) was shown to enhance heart function and survival after MI in mice [29]. The gene discussed is CXCL12; the disease is myocardial infarction.